GLAUKOS Corp reported second-quarter 2026 results with revenue of $185.6M, up from $124.1M a year earlier, while the company posted a net loss of $18.4M and diluted net loss per share of $(0.31), modestly improved from the prior-year quarter — 10-Q Summary.
Financial Highlights
- Revenue was $185.6M for Q2 2026, compared with $124.1M in Q2 2025; YoY change 50%.
- Net income (loss) was a loss of $18.4M for Q2 2026, compared with a loss of $19.7M in Q2 2025; loss narrowed ~7% YoY.
- Diluted earnings per share was a loss of $(0.31) for Q2 2026, compared with $(0.34) in Q2 2025.
Business Highlights
- Revenue growth: Net sales rose about 50% year‑over‑year for Q2 and about 46% year‑to‑date, driven by higher iDose TR and Epioxa volumes.
- Channel shift: U.S. mix moved toward ambulatory surgery center (ASC) procedures, representing roughly 80% of iDose/iStent volumes, and the company expanded direct sales for Epioxa.
- Commercial momentum: Epioxa commercial rollout advanced and GLAUKOS secured a permanent HCPCS J2789 code effective July 1, 2026.
- Operational scaling: Management is increasing manufacturing and commercial infrastructure, including an estimated $80M capital investment in a new 200k sq ft Huntsville facility.
- R&D and pipeline: Research and development spending rose about 39–40% to support next‑generation iDose, Epioxa programs and other glaucoma and retinal candidates.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.